Brokerages Set ICON Public Limited (NASDAQ:ICLR) Price Target at $351.60

Shares of ICON Public Limited (NASDAQ:ICLR) have earned an average rating of “Buy” from the twelve analysts that are currently covering the company, Marketbeat reports. Eleven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $351.60.

A number of brokerages recently weighed in on ICLR. Robert W. Baird decreased their price objective on shares of ICON Public from $368.00 to $340.00 and set an “outperform” rating for the company in a report on Friday, September 20th. Truist Financial reaffirmed a “buy” rating and set a $383.00 price target on shares of ICON Public in a research note on Wednesday, September 11th. StockNews.com cut ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Barclays decreased their target price on ICON Public from $355.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday, July 26th. Finally, Leerink Partnrs raised ICON Public to a “strong-buy” rating in a research report on Wednesday, September 18th.

Institutional Trading of ICON Public

A number of institutional investors have recently modified their holdings of ICLR. CIBC Private Wealth Group LLC lifted its position in ICON Public by 0.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 695,932 shares of the medical research company’s stock valued at $196,998,000 after acquiring an additional 6,331 shares during the last quarter. State of Tennessee Treasury Department lifted its holdings in shares of ICON Public by 4.9% during the 4th quarter. State of Tennessee Treasury Department now owns 155,797 shares of the medical research company’s stock valued at $44,101,000 after purchasing an additional 7,270 shares during the last quarter. Kornitzer Capital Management Inc. KS boosted its position in shares of ICON Public by 15.9% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock worth $30,016,000 after purchasing an additional 13,163 shares in the last quarter. GAMMA Investing LLC grew its stake in ICON Public by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock worth $82,000 after buying an additional 87 shares during the last quarter. Finally, Riverview Trust Co acquired a new position in ICON Public during the 1st quarter valued at about $31,000. 95.61% of the stock is currently owned by institutional investors.

ICON Public Stock Performance

Shares of NASDAQ:ICLR opened at $285.61 on Tuesday. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.36. ICON Public has a 12 month low of $221.20 and a 12 month high of $347.72. The company has a market capitalization of $23.56 billion, a price-to-earnings ratio of 34.75, a PEG ratio of 1.32 and a beta of 1.22. The firm’s 50-day moving average is $312.40 and its 200 day moving average is $316.45.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, July 24th. The medical research company reported $3.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.68 by $0.07. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The business had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.14 billion. During the same quarter in the previous year, the business earned $2.96 earnings per share. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. Research analysts predict that ICON Public will post 14.54 EPS for the current year.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.